MA28515B1 - Inhibiteurs de gsk-3 - Google Patents
Inhibiteurs de gsk-3Info
- Publication number
- MA28515B1 MA28515B1 MA29364A MA29364A MA28515B1 MA 28515 B1 MA28515 B1 MA 28515B1 MA 29364 A MA29364 A MA 29364A MA 29364 A MA29364 A MA 29364A MA 28515 B1 MA28515 B1 MA 28515B1
- Authority
- MA
- Morocco
- Prior art keywords
- gsk
- inhibitors
- compounds
- thiadiazolidinc
- alzheimer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04075997A EP1586318A1 (fr) | 2004-04-05 | 2004-04-05 | Thiazolidinones comme inhibiteurs de GSK-3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28515B1 true MA28515B1 (fr) | 2007-04-03 |
Family
ID=34928129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29364A MA28515B1 (fr) | 2004-04-05 | 2006-10-02 | Inhibiteurs de gsk-3 |
Country Status (30)
Country | Link |
---|---|
US (2) | US7531561B2 (fr) |
EP (2) | EP1586318A1 (fr) |
JP (1) | JP4995076B2 (fr) |
KR (1) | KR101151647B1 (fr) |
CN (1) | CN1946398B (fr) |
AR (2) | AR048820A1 (fr) |
AT (1) | ATE446090T1 (fr) |
AU (1) | AU2005230392B2 (fr) |
BR (1) | BRPI0508788A (fr) |
CA (1) | CA2559740C (fr) |
CY (1) | CY1109724T1 (fr) |
DE (1) | DE602005017215D1 (fr) |
DK (1) | DK1586319T3 (fr) |
EC (1) | ECSP066858A (fr) |
ES (1) | ES2335505T3 (fr) |
HK (1) | HK1100426A1 (fr) |
HR (1) | HRP20100032T1 (fr) |
IL (1) | IL178125A (fr) |
MA (1) | MA28515B1 (fr) |
MX (1) | MXPA06011194A (fr) |
NO (1) | NO332751B1 (fr) |
NZ (1) | NZ549904A (fr) |
PL (1) | PL1586319T3 (fr) |
PT (1) | PT1586319E (fr) |
RS (1) | RS51340B (fr) |
RU (1) | RU2379300C2 (fr) |
SI (1) | SI1586319T1 (fr) |
TW (1) | TWI352084B (fr) |
WO (1) | WO2005097117A1 (fr) |
ZA (1) | ZA200608221B (fr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE366238T1 (de) | 2000-05-11 | 2007-07-15 | Consejo Superior Investigacion | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 |
EP1586318A1 (fr) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiazolidinones comme inhibiteurs de GSK-3 |
WO2006045581A1 (fr) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | Utilisation de 1, 2, 4-thiadiazolidine-3, 5-diones en tant qu'activateurs de ppar |
ES2258406B1 (es) * | 2005-02-10 | 2007-12-01 | Neuropharma, S.A. | Uso de compuestos heterociclicos como agentes neurogenicos. |
EP1749523A1 (fr) * | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | Des inhibiteurs de GSK-3 |
AU2007275686B2 (en) * | 2006-07-18 | 2013-10-31 | University Of Rochester | Thiadiazolidinone derivatives |
WO2008012031A2 (fr) * | 2006-07-25 | 2008-01-31 | Universität Bern | Bloqueurs de gsk3 de prévention et de traitement de pemphigus vulgaire |
EP2061767B1 (fr) | 2006-08-08 | 2014-12-17 | Sanofi | Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation |
KR20090071662A (ko) | 2006-10-21 | 2009-07-01 | 애보트 게엠베하 운트 콤파니 카게 | 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도 |
KR100837785B1 (ko) * | 2007-01-17 | 2008-06-13 | 한국화학연구원 | 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 |
KR100829468B1 (ko) * | 2007-01-17 | 2008-05-16 | 한국화학연구원 | 신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법 |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
EP2242745A1 (fr) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
EP2177510A1 (fr) | 2008-10-17 | 2010-04-21 | Universität des Saarlandes | Modulateurs allostériques de protéine kinase |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
RU2012111354A (ru) | 2009-08-26 | 2013-10-10 | Санофи | Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
WO2011151359A1 (fr) * | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
EP2621914B1 (fr) | 2010-09-27 | 2016-12-28 | Abbott GmbH & Co. KG | Composés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la glycogène synthase kinase-3 |
WO2012065065A1 (fr) * | 2010-11-12 | 2012-05-18 | Follica, Inc. | Procédés et compositions pour moduler la pousse de cheveux, la cicatrisation de plaie et la révision de cicatrice |
WO2012078649A1 (fr) | 2010-12-06 | 2012-06-14 | Follica, Inc. | Procédés destinés à traiter la calvitie et à favoriser la croissance des cheveux |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
EP2683698B1 (fr) | 2011-03-08 | 2017-10-04 | Sanofi | Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation |
EP2683700B1 (fr) | 2011-03-08 | 2015-02-18 | Sanofi | Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation |
EP2683705B1 (fr) | 2011-03-08 | 2015-04-22 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683702B1 (fr) | 2011-03-08 | 2014-12-24 | Sanofi | Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683703B1 (fr) | 2011-03-08 | 2015-05-27 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
US8865750B2 (en) | 2011-04-28 | 2014-10-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of RGS proteins |
EP2527323A1 (fr) | 2011-05-24 | 2012-11-28 | Noscira, S.A. | Dérivés de disulfure de carbonyle d'urée et leurs utilisations thérapeutiques |
WO2012170657A1 (fr) * | 2011-06-07 | 2012-12-13 | Georgetown University | Ciblage de gsk-3 bêta pour le traitement de la maladie de parkinson |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
EP2760862B1 (fr) | 2011-09-27 | 2015-10-21 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
JP6073377B2 (ja) * | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーAsd Therapeutics Partners Llc | Gsk−3阻害剤としての新規チアジアゾリジンジオン |
RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
CN103992313A (zh) * | 2013-02-18 | 2014-08-20 | 江苏欧威医药有限公司 | 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途 |
CN103992312A (zh) * | 2013-02-18 | 2014-08-20 | 江苏欧威医药有限公司 | 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用 |
WO2015075051A1 (fr) | 2013-11-19 | 2015-05-28 | Universitaet Des Saarlandes | Inhibiteurs allostériques de protéines kinases c atypiques |
US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
WO2015192078A1 (fr) | 2014-06-12 | 2015-12-17 | Cedars-Sinai Medical Center | Compositions et procédés de traitement de cancers |
CN107151235B (zh) * | 2016-03-04 | 2019-12-13 | 上海市计划生育科学研究所 | 噻二唑烷二酮基gsk3抑制剂在调节***运动能力中的用途 |
JP2019511495A (ja) * | 2016-03-10 | 2019-04-25 | アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ | GSK3β阻害薬チデグルシブによるCDKL5障害の治療 |
WO2018226721A1 (fr) * | 2017-06-06 | 2018-12-13 | The J. David Gladstone Institutes | Compositions et méthodes de réactivation d'un virus d'immunodéficience latent au moyen d'un inhibiteur de gsk-3 |
WO2021209563A1 (fr) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire |
CN113827592A (zh) * | 2020-06-24 | 2021-12-24 | 中国科学院上海药物研究所 | 一种噻二唑烷二酮基化合物在治疗致病性感染中的应用 |
EP4298088A1 (fr) | 2021-02-24 | 2024-01-03 | Teva Pharmaceuticals International GmbH | Formes à l'état solide de tideglusib et leur procédé de préparation |
EP4340832A1 (fr) | 2021-05-21 | 2024-03-27 | Amo Pharma Ltd. | Procédé de traitement de maladies à médiation par des répétitions d'arn ayant un composé de liaison de répétition d'arn |
EP4094760A1 (fr) | 2021-05-24 | 2022-11-30 | Consejo Superior De Investigaciones Científicas | Thiadiazolidinones pour leur utilisation dans le traitement de la dystrophie scapulo-humérale |
CN115197167B (zh) * | 2022-07-22 | 2023-07-28 | 中国药科大学 | 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
ATE366238T1 (de) * | 2000-05-11 | 2007-07-15 | Consejo Superior Investigacion | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 |
EP1586318A1 (fr) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiazolidinones comme inhibiteurs de GSK-3 |
-
2004
- 2004-04-05 EP EP04075997A patent/EP1586318A1/fr not_active Withdrawn
-
2005
- 2005-04-01 AR ARP050101293A patent/AR048820A1/es not_active Application Discontinuation
- 2005-04-04 BR BRPI0508788-0A patent/BRPI0508788A/pt not_active IP Right Cessation
- 2005-04-04 PT PT05075779T patent/PT1586319E/pt unknown
- 2005-04-04 AT AT05075779T patent/ATE446090T1/de active
- 2005-04-04 JP JP2007506716A patent/JP4995076B2/ja active Active
- 2005-04-04 CA CA2559740A patent/CA2559740C/fr active Active
- 2005-04-04 CN CN2005800121414A patent/CN1946398B/zh active Active
- 2005-04-04 WO PCT/EP2005/003613 patent/WO2005097117A1/fr active Application Filing
- 2005-04-04 AU AU2005230392A patent/AU2005230392B2/en active Active
- 2005-04-04 SI SI200530879T patent/SI1586319T1/sl unknown
- 2005-04-04 EP EP05075779A patent/EP1586319B1/fr active Active
- 2005-04-04 RS RSP-2010/0017A patent/RS51340B/en unknown
- 2005-04-04 RU RU2006139030/04A patent/RU2379300C2/ru active
- 2005-04-04 ZA ZA200608221A patent/ZA200608221B/xx unknown
- 2005-04-04 NZ NZ549904A patent/NZ549904A/en active IP Right Revival
- 2005-04-04 ES ES05075779T patent/ES2335505T3/es active Active
- 2005-04-04 DK DK05075779.8T patent/DK1586319T3/da active
- 2005-04-04 TW TW094110769A patent/TWI352084B/zh active
- 2005-04-04 MX MXPA06011194A patent/MXPA06011194A/es active IP Right Grant
- 2005-04-04 DE DE602005017215T patent/DE602005017215D1/de active Active
- 2005-04-04 PL PL05075779T patent/PL1586319T3/pl unknown
- 2005-04-05 US US11/098,610 patent/US7531561B2/en active Active
-
2006
- 2006-09-14 IL IL178125A patent/IL178125A/en active IP Right Grant
- 2006-09-18 EC EC2006006858A patent/ECSP066858A/es unknown
- 2006-10-02 MA MA29364A patent/MA28515B1/fr unknown
- 2006-10-02 NO NO20064456A patent/NO332751B1/no unknown
- 2006-10-11 KR KR1020067021121A patent/KR101151647B1/ko active IP Right Grant
-
2007
- 2007-07-31 HK HK07108359.1A patent/HK1100426A1/xx unknown
-
2009
- 2009-04-22 US US12/428,442 patent/US8158661B2/en active Active
-
2010
- 2010-01-13 CY CY20101100036T patent/CY1109724T1/el unknown
- 2010-01-18 HR HR20100032T patent/HRP20100032T1/hr unknown
-
2016
- 2016-04-27 AR ARP160101182A patent/AR104417A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28515B1 (fr) | Inhibiteurs de gsk-3 | |
EA200901373A1 (ru) | Аминогетероциклические соединения | |
WO2006103120A3 (fr) | Nouveaux composes heterocycliques, preparation et utilisation en tant que medicaments, notamment en tant qu'agents anti-alzheimer | |
DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
SV2006002055A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
SE0102299D0 (sv) | Compounds | |
BRPI0417543A (pt) | quinolinas úteis no tratamento de doença cardiovascular | |
EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
CL2007002288A1 (es) | Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro | |
ATE523495T1 (de) | Substituierte pyrazolinverbindungen, deren herstellung und verwendung als medikamente | |
DE602004016850D1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
EP1817312A4 (fr) | Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer | |
UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
DOP2005000049A (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos | |
ATE403428T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
DE602004019778D1 (de) | Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen | |
ATE435650T1 (de) | 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen | |
BRPI0509881A (pt) | combinação terapêutica para tratamento da doença de alzheimer | |
UY28842A1 (es) | Inhibidores de gsk-3 |